Laterosporulin25: A probiotically produced, novel defensin-like bacteriocin and its immunogenic properties

• Published in: International immunopharmacology Vol. 121; p. 110500
• Main Authors: Dinata, Roy, Baindara, Piyush
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2023
• Subjects: Bacteriocins; Bacteriocins - chemistry; Bacteriocins - pharmacology; Brevibacillus laterosporus; Carrier Proteins; Carrier-protein; Computational Biology; Defensins; Defensins - pharmacology; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Immunoinformatics; Molecular Docking Simulation; Probiotic; Subunit vaccine; Vaccines, Subunit; Probiotic; Defensins; Subunit vaccine; Carrier-protein; Brevibacillus laterosporus; Bacteriocins; Immunoinformatics
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2023.110500

•The present work identified and characterized, LS25, a probiotically produced novel defensin like AMP.•Immunogenic and physicochemical properties of LS25 have been characterized.•In Silico immune simulations have been performed to demonstrate the immune response caused by LS25.•LS25 is suggested to be used as an adjuvant or carrier protein for subunit vaccine development. Although multiple vaccines have been developed against infectious diseases, the rapid emergence of new pathogens develops an urgent need for novel strategies to combat infectious diseases. Antimicrobial peptides (AMPs) are excellent agents to fight against infectious diseases having unique multiple mechanisms of action against various pathogens. Apart from the direct applications, AMPs can also be developed as subunit vaccines or could be used as a highly immunogenic carrier protein with highly antigenic but non-immunogenic antigens. Here in the present study, we have identified a novel defensin-like bacteriocin, laterosporulin25 (LS25) upon genome mining of Brevibacillus laterosporus DSM25, a probiotic bacterial strain. By using immunoinformatic tools, we have studied the immunogenic and physiochemical properties of LS25. LS25 is characterized as defensin-like bacteriocin, having 51 amino acids and a molecular weight of 5862.7 Da. The modeled tertiary structure of LS25 is docked with TLR3 and TLR4-MD2 complex to confirm the facilitation of induced immune response that is further validated using molecular dynamics simulations and In-silico immune stimulations. Overall, detailed immunoinformatics analysis suggested LS25 as a potential candidate to be used as an adjuvant or carrier protein for subunit vaccine development, however, further in-vitro and in-vivo experiments are essential to validate its potential.